NEWSpublisher 2007 :: AngloChinese Investments
date from:
date to:
search for string:
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY NEWS » Company watch » TOP 50 Pharmas » Merck & Co  1    
found files: 7
Merck & Co »28/07/2008 [Company watch]
Huahai Pharmaceutical to Produce Patent Drug for Merck

Both sides have inked an agreement. Huahai Pharmaceutical will be responsible for production of a patent drug for Merck, covering formulation, production and packaging of the drug, and the US firm will exclusively sell the products in the international market....   more»

Merck & Co »04/09/2008 [Company watch]
Merck Serono and Ablynx Enter into an Agreement to Co-Discover and Co-Develop Nanobodies®

• Merck Serono and Ablynx to equally contribute to discover and develop Nanobodies® against two targets in oncology and immunology and equally share the resulting profits Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced that it has entered into an agreement with Ablynx (Euronext Brussels: ABLX), to co-discover and co-develop Nanobodies® against two targets in oncology and immunology. The agreement includes an upfront cash payment to Ablynx of €10 million. Nanobodies® are a new class of therapeutic proteins that contain the unique structural and functional properties of naturally-occurring single domain antibodies. The partners will collaborate to research and develop Nanobody®-based therapeutics against two disease targets exploiting some of the key benefits Nanobodies® have over conventional antibodies and other fragments. Under the terms of the agreement, both companies will equally share all research and development costs. Should Ablynx contribute equally to each program, it will be eligible to receive fifty percent of the resulting profits. In addition, Ablynx will have an option to opt-out partly or fully during the research and development programs, in which case the company would be eligible to receive either a reduced profit share, in the case of a partial opt-out, or milestones and royalties on potential sales, in the case of a full opt- out. Total development and commercial milestones, depending on the point of opt-out by Ablynx, could reach up to €325 million should a product be approved in multiple indications in all major markets. “This collaboration reinforces our commitment to deliver innovative treatments in areas of high unmet medical needs,” said Dr Bernhard Kirschbaum, Executive Vice President Research of Merck Serono. "We believe that Nanobodies® have the potential to provide innovative drugs combining the best features of monoclonal antibodies and small molecules, and we look forward to working with Ablynx." "We are very pleased to enter into this partnership with Merck Serono, a recognized global leader in the treatment of oncology and immunology therapies. This type of risk and reward sharing collaboration underlines Ablynx’s maturing capabilities and collaboration strategy, whereby we can leverage on the resources and expertise of our partners to advance Nanobodies® more quickly into the clinic while retaining an equal share of the value created", commented Dr Edwin Moses, CEO and Chairman of Ablynx....   more»

Merck & Co »14/12/2008 [Company watch]
Merck to move into biotech market

Merck has announced plans to move into biotechnology medicine and break into the generic biotech market....   more»

Merck & Co »12/03/2009 [Company watch]
How Will the Merck / SGP Merger Affect China?

Merck has offered $41.1 billion to acquire fellow big pharma Schering-Plough, an acquisition that, if completed, is expected to close in Q4 of 2009....   more»

Merck & Co »30/09/2009 [Company watch]
Merck Acquires Leading Manufacturer of Effect Pigments in China

Within the scope of this transaction, Merck has acquired the production site of Taizhu in Taicang, 40 km from Shanghai, as well as the entire sales and marketing organization in China and abroad for a total consideration of € 28 million....   more»

Merck & Co
»25/11/2009 [Company watch]
Merck Serono to Spend $225 Million on New Beijing R&D Center

Merck Serono, a division of Germany’s Merck KGaA (MRK), will build a global R&D center in Beijing, China, spending $225 million over the next four years. The center, which will eventually house 200 employees, will be the fourth major R&D center for the company. The Beijing center will be tasked with meeting unmet needs in China’s public health system. Merck Serono positioned the center as proof of the company’s commitment to the pharmaceutical market in China....   more»

Merck & Co »14/12/2009 [Company watch]
Merck Starts China Trial of Cancer Vaccine

Merck KGaA (MRK) of Germany will conduct a multi-national Phase III clinical trial of the therapeutic cancer vaccine Stimuvax in Asian patients....   more»

AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.